Patents

Introgen Gets Worldwide License For Anticancer Therapy

Published in Gene Therapy Weekly, October 18th, 2001

The U.S. Patent and Trademark Office has issued to the Board of Regents of The University of Texas System a patent covering the administration of chemotherapeutic drugs, radiation therapies, or other agents that have a damaging effect on the DNA of cancer cells, to a cancer patient, followed by administration of gene therapy, regardless of the gene used in the therapy.

The patent is one of numerous patents, pending or issued, that Introgen Therapeutics Inc. has licensed exclusively from The University of Texas System based on technology from the University of Texas M.D. Anderson Cancer Center.

Virtually all cancer patients receive DNA-damaging agents...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-10-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry